For instance, PSMA-targeted positron emission tomography (PET)/computed tomography (CT) has gained increasing acceptance in the diagnosis of prostate cancer (PC) due to its superior accuracy in identifying metastases compared to both CT and magnetic resonance imaging (MRI) [7,8]. This evidence concerns the gene FOLH1 and prostate cancer.